AstraZeneca Spurns Pfizer Bid, Earnings News & a Jim Cramer Pick
LinkedIn is among loss leaders on the tech scene in 2014, and its earnings report Thursday did little to improve investors' outlook.
Pfizer sweetened its bid to buy out British pharma company Astrazeneca--a move that would also shift the tax base of the American company overseas--but its target spurned its $106 billion bid. LinkedIn is among loss leaders on the tech scene in 2014, and its earnings report Thursday did little to improve investors' outlook. And Jim Cramer's driving away with one of the biggest positions in his fund, making a bigger bet on a new management team. May 2, 2014 at the Nasdaq Marketsite in Times Square.
